SkinBioTherapeutics PLC Appointment of Joint Broker (0278B)
05 January 2018 - 6:00PM
UK Regulatory
TIDMSBTX
RNS Number : 0278B
SkinBioTherapeutics PLC
05 January 2018
SkinBioTherapeutics plc
Appointment of Joint Broker
Manchester, UK - 5 January 2018 - SkinBioTherapeutics plc (AIM:
SBTX, the "Company"), a life science company focused on skin
health, announces the appointment of Northland Capital Partners to
act as the Company's Joint Corporate Broker, alongside Turner Pope
Investments, with immediate effect.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
-Ends-
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0)
Dr. Cath O'Neill, CEO 161 468 2760
Doug Quinn, CFO
Cairn Financial Advisers LLP Tel: +44 (0)
(Nominated Advisor) 20 7213 0880
Tony Rawlinson / Emma Earl /
Richard Nash
Turner Pope Investments (Joint Tel: +44 (0)
Broker) 20 3621 4120
Ben Turner / James Pope
Northland Capital Partners (Joint Tel: +44 (0)
Broker) 20 3861 6625
John Howes / Tom Price
Instinctif Partners (Media Relations) Tel: +44 (0)
Melanie Toyne-Sewell / Deborah 20 7457 2020
Bell SkinBio@instinctif.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine
O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made
on the activities of lysates derived from probiotic bacteria when
applied to the skin. The Company has shown that the SkinBiotix(R)
platform can improve the barrier effect of skin models, protect
skin models from infection and repair skin models. Proof of
principle studies have shown that the SkinBiotix(R) platform has
beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer
office of the University of Manchester for the discovery of
SkinBiotix(R). The platform was subsequently spun out of the
University of Manchester in March 2016 and was funded by OptiBiotix
(AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising
GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information,
visit www.skinbiotherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPBRGDBGGGBGIS
(END) Dow Jones Newswires
January 05, 2018 02:00 ET (07:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024